N-Acetyl-L-Cysteine
Niemann-Pick Disease, Type C
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Phase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Niemann-Pick Disease, Type C cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Miglustat Actelion | Phase 4 | BBB |
az-3102 Azafaros B.V. | Phase 3 | BB |
Nizubaglustat Azafaros B.V. | Phase 3 | B |
N-Acetyl-L-Leucine IntraBio Inc | Phase 3 | B |
2-HYDROXYPROPYL BETA-CYCLODEXTRIN (DS 4.2) Vtesse, LLC, a Mallinckrodt Pharmaceuticals Company | Phase 2/3 | B |
View all 11 →
Same molecule, other indications
N-Acetyl-L-Cysteine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →